FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

horizontal rule

September 21, 2004

Dear Colleague:

Small Business Outreach

This communication is part of our outreach to small businesses in response to the President's Executive Order 13272, "Proper Consideration of Small Entities in Agency Rulemaking." In accordance with the principles set forth in this Executive Order, we want to provide you with the opportunity for meaningful and timely input in the development of regulatory policies that may have substantial direct effects on you.

The Food and Drug Administration (FDA) has adopted this process to enhance small entities' input by sending notice of the publication of the Unified Agenda of Federal Regulations (Agenda). With this notice and the information we provide on locating the Agenda on the Internet, we send a list of those regulatory items that we believe will be of particular interest to you.

Executive Order 13272 promotes compliance with the Regulatory Flexibility Act which requires Federal agencies to examine the impact of regulations on small entities. As part of this analysis, an agency is required to determine whether or not a rule will have "a significant economic impact on a substantial number of small entities." In the Agenda, there is a section where agencies can indicate whether or not a regulatory flexibility analysis is needed. If the agency has either not made that determination yet or has determined that no analysis is required, it may still indicate that some impact on small entities is likely by indicating that in the "Small Entities Affected" section. Please note that the list that we have enclosed with this letter includes both those regulations for which FDA has determined that a regulatory flexibility analysis is required and those for which some impact is likely or "undetermined," but which may not require a full analysis.

For your information, under section 610(c) of the Regulatory Flexibility Act, Federal agencies are required to review regulations that have or will have a "significant economic impact on a substantial number of small entities" within 10 years of publication in the Federal Register. The purpose of this review is to determine whether the rule should continue without change, be amended or rescinded to minimize the impact on small entities. To comply with this requirement, FDA has implemented the process of identifying these rules to be reviewed under section 610(c) in the Agenda. You will note that by the title of these rules FDA has placed the phrase "(610 section review)." In the abstract in the Agenda for these rules, FDA explains the 610 section review and solicits comments on a list of questions regarding the need for the rule. In this issue of the Agenda, FDA announced the completion of one such review. However, there are no new 610(c) reviews being undertaken by the agency at this time.

Information for You on the Unified Agenda of Federal Regulations (Agenda)

The Agenda provides, among other things, abstracts of all proposed and final regulations currently planned by the FDA for the next six to twelve months, as well as abstracts of planned long-term actions and completed actions. Each Agenda item also contain an indication as to whether or not small businesses may be affected. The Agenda is published in the Federal Register twice a year (usually in April and October), with the Fall edition also containing the Regulatory Plan. Below is a listing of 35 rulemakings in the Agenda that we have identified that will impact small entities, and a listing of 18 rulemakings with an "Undetermined" impact on small entities. We encourage you to review these abstracts and to provide any comments or raise any questions you may have with the contact person listed, or you may contact Mr. Richard Barnes of the FDA's Division of Federal-State Relations at 301-827-6906.

The Agenda for the Food and Drug Administration for Spring 2004, which published in the Federal Register on June 28, 2004, can be found on the web at the following two locations:

1. a) Go to Internet site http://www.archives.gov
b) On the left-hand side of the screen click on "Federal Register"
c) Under the heading "Sections," click on "Online Publications via GPO Access"
d) Scroll down to "Unified Agenda" and click
e) You can either enter a page number provided in our list in the "Quick Search" or browse the Table of Contents

2. a) Go to Internet site http://www.reginfo.gov
b) Click on "Unified Agenda & Regulatory Plan"
c) Click on "Spring 2004 Unified Agenda of Federal Regulatory and Deregulatory Actions"
d) Click on "Databases and Browseable List of the Spring 2004 Unified Agenda"
e) Click on "Unified Agenda Tables of Contents"
f) Click on "Department of Health and Human Services (HHS)" and scroll to the Food and Drug Administration agenda.

Suggestions Are Welcome

We welcome suggestions and other comments from you on FDA's activities to enhance your input in the development of FDA's regulations, especially those regulations that have a substantial and direct effect on you. Again, you may send your comments and suggestions to the contact person listed for a particular Federal Register document or by contacting Mr. Richard Barnes of the FDA's Division of Federal-State Relations or to me.

In addition, we would like to take this opportunity to tell you about FDA's web site for small businesses. It can be found at http://www.fda.gov/ora/fed_state/Small_Business/sb_guide/default.htm. This site provides information on FDA Small Business contacts, how to participate in various FDA forums, and provides guidance on how to get assistance from the agency.

Sincerely,

 

Edwin V. Dutra, Jr.
Director, Regulations Policy and Management Staff
Office of Policy, Planning and Legislation
5600 Fishers Lane (HF-26)
Parklawn Building Room 12-A-11
Rockville, MD 20857

Phone: 301-827-3480
Fax: 301-827-1696
e-mail: EDUTRA@OC.FDA.GOV

Enclosures: List of 35 Rulemakings Identified by FDA with Impact on Small Entities and List of 18 Rulemakings Identified by FDA with "Undetermined" Impact on Small Entities. All of which can be found in the Unified Agenda which published in the Federal Register on June 28, 2004.

FDA IDENTIFIED RULEMAKINGS WITH IMPACT ON SMALL ENTITIES

  1. "Safety Reporting Requirements for Human Drug and Biological Products," Sequence No. 833, page 37442
  2. "Over-the-Counter (OTC) Drug Review; Sunscreen Products," Sequence No. 836, page 37443
  3. "Foreign and Domestic Establishment Registration and Listing Requirements for Drugs and Biologics," Sequence No. 837, page 37443
  4. "Prevention of Salmonella Enteritidis in Shell Eggs," Sequence No. 839, page 37444
  5. "Food Standards: General Principles and Food Standards Modernization," Sequence No. 842, page 37445
  6. "Positron Emission Tomography Drugs; Current Good Manufacturing Practices," Sequence 843, page 37445
  7. "Health Claims," Sequence No. 846, page 37446
  8. "Quality Standard Regulation Establishing Allowable Level for Arsenic in Bottled Water," Sequence No. 847, page 37446
  9. "Cochineal Extract and Carmine Label Declaration," Sequence No. 849, page 37447
  10. "OTC Drug Review; Cough/Cold (Bronchodilator) Products," Sequence No. 857, page 37449
  11. "OTC Drug Review; Cough/Cold (Combination) Products," Sequence No. 858, page 37450
  12. "OTC Drug Review; Cough/Cold (Nasal Decongestant) Products," Sequence No. 859, page 37450
  13. "OTC Drug Review; Internal Analgesic Products," Sequence No. 860, page 37450
  14. "OTC Drug Review; Labeling of Drug Products for OTC Human Use," Sequence No. 861, page 37450
  15. "OTC Drug Review; Weight Control Products," Sequence No. 862, page 37451
  16. "Labeling for Human Prescription Drugs; Revised Format," Sequence No. 864, page 37451
  17. "Current Good Tissue Practice for Manufacturers of Human Cell, Tissue, and Cellular and Tissue-Based Product Establishments; Inspection and Enforcement," Sequence No. 865, page 37452
  18. "Current Good Manufacturing Practice in Manufacturing, Packing, or Holding Dietary Ingredients and Dietary Supplements," Sequence No.867, page 37452
  19. "Amendments to the Performance Standards for Diagnostic X-ray Systems and Their Major Components," Sequence No. 870, page 37453
  20. "Establishment and Maintenance of Records Pursuant to the Public Health Security and Bioterrorism Preparedness and Response Act of 2002," Sequence No. 871, page 37454
  21. "Registration of Food and Animal Feed Facilities," Sequence No. 872, page 37454
  22. "Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002," Sequence No. 873, page 37455
  23. "OTC Drug Review; Antiperspirant Products," Sequence No. 877, page 37456
  24. "OTC Drug Review; Cough/Cold (Antihistamine) Products," Sequence No. 878, page 37457
  25. "OTC Drug Review; Ophthalmic Products," Sequence No. 879, page 37457
  26. "OTC Drug Review; Skin Protectant Products," Sequence No. 880, page 37457
  27. "OTC Drug Review; Vaginal Contraceptive Products," Sequence No. 881, page 37457
  28. "Chronic Wasting Disease: Control of Food Products and Cosmetics Derived from Exposed Animal Populations," Sequence No. 883, page 37458
  29. "Requirements for Submission of In Vivo Bioequivalence Data," Sequence No. 884, page 37458
  30. "Toll-Free Number for Reporting Adverse Events on Labeling for Human Drugs," Sequence No. 885, page 37459
  31. "Submission of Standardized Electronic Study Data from Clinical Studies Evaluating Human Drugs and Biologics," Sequence No. 887, page 37459
  32. "Food Labeling; Food Allergen Ingredient Labeling," Sequence No.889, page 37460
  33. "OTC Drug Review; External Analgesic Products," Sequence No. 893, page 37461
  34. "OTC Drug Review; Laxative Drug Products," Sequence No. 894, page 37461
  35. "OTC Drug Review; Oral Health Care Products," Sequence No. 895, page 37462

FDA IDENTIFIED RULEMAKINGS WITH "UNDETERMINED" IMPACT ON SMALL ENTITIES

  1. "Food Labeling; Prominence of Calories," Sequence No. 834, page 37442
  2. "Food Labeling; Serving Sizes," Sequence No. 835, page 37442
  3. "Applications for FDA Approval to Market a New Drug; Complete Response Letter; Amendments to Unapproved Applications," Sequence No. 838, page 37443
  4. "Medical Devices; Anesthesiology Devices; Proposed Reclassification of Pressure Regulators for Use with Medical Oxygen," Sequence No. 841, page 37444
  5. "Reporting Information Regarding Falsification of Data," Sequence No. 844, page 37445
  6. "Definition of "Serious Adverse Health Consequences" Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002," Sequence No. 845, page 37446
  7. "Content and Format of Labeling for Human Prescription Drugs and Biologics; Requirements for Pregnancy and Lactation," Sequence No. 848, page 37447
  8. "Charging for Investigational Drugs," Sequence No. 850, page 37447
  9. "Treatment Use of Investigational Drugs," Sequence No. 851, page 37447
  10. "Use of Ozone-Depleting Substances; Removal of Essential Use Designation; Albuterol," Sequence No. 853, page 37448
  11. "Latex Condoms: Special Controls," Sequence No. 855, page 37449
  12. "Blood Initiative: Regulations for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use," Sequence No. 856, page 37449
  13. "CGMP for Blood and Blood Components: Notification of Consignees and Transfusion Recipients Receiving Blood and Blood Components At Increased Risk of Transmitting HCV Infection (Lookback)," Sequence No. 866, page 37452
  14. "Human Subject Protection; Foreign Clinical Studies Not Conducted Under an IND," Sequence No. 875, page 37456
  15. "Blood Initiative: Revisions to Labeling and Storage Requirements for Blood and Blood Components, Including Source Plasma," Sequence No. 876, page 37456
  16. "Requirements Pertaining to Sampling Services and Private Laboratories Used in Connection with Imported Foods," Sequence No. 882, page 37458
  17. "Medical Gas Containers and Closures; Current Good Manufacturing Practice Requirements," Sequence No. 888, page 37460
  18. "Current Good Manufacturing Practice in Manufacturing, Processing, Packing or Holding of Drugs; Revision of Certain Labeling Controls," Sequence No. 890, page 37460

*Abstracts of these planned rulemakings appear in the Unified Agenda of Federal Regulations on the pages indicated. The Agenda published in the Federal Register on December 22, 2003. It may be found on the Internet at http://www.archives.gov or at http://www.reginfo.gov (see letter for instructions).

horizontal rule